With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
A handful of other states are considering mandating private insurance coverage of the technology, used to block ...
Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
Verywell Health on MSN
When is chemotherapy not recommended?
Chemotherapy is not recommended if the risks are greater than the benefits. Chemotherapy can harm a developing baby and might ...
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
Loqtorzi (toripalimab) showed significant improvement in progression-free survival for acral melanoma compared to standard chemotherapy in a phase 3 trial. Acral melanoma, a rare and aggressive ...
News-Medical.Net on MSN
New breakthrough could modernize treatment for glioblastoma
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...
Morning Overview on MSN
New discovery could prevent chemo nerve pain that won’t quit
Chemotherapy has long forced patients to choose between fighting their cancer and living with nerve pain that can linger for ...
Andy Gissing, 62, from Portsmouth, Hampshire, is now trying to fund privately a 'last hope' treatment - and that without it ...
In a groundbreaking development, First Ascent Biomedical unveils a compelling narrative of resilience and innovation through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback